Lockheed Martin Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Lockheed Martin Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-10,000	Closed	-$171K	–	126
2018 Q1	$171K	Hold	10,000	–	–	0.01%	127
2017 Q4	$189K	Sell	10,000 -8,000	-44%	-$120K	0.01%	126
2017 Q3	$317K	Buy	+18,000	New	+$405K	0.02%	131
2016 Q1	–	Sell	-13,000	Closed	-$853K	–	100
2015 Q4	$853K	Buy	+13,000	New	+$803K	0.08%	62

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Lockheed Martin Investment Management's TEVA Position: Q2 2018 in Review

Lockheed Martin Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2018, closing a stake of 10,000 shares — an estimated $171K sold.

Lockheed Martin Investment Management first reported a position in TEVA in Q4 2015 and held it in 4 quarters. The position peaked at $853K in Q4 2015. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2018.

Lockheed Martin Investment Management reported no remaining Teva Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Lockheed Martin Investment Management sold 10,000 Teva Pharmaceuticals shares in Q2 2018, an estimated $171K.
Lockheed Martin Investment Management first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 4 quarters.
Lockheed Martin Investment Management's Teva Pharmaceuticals position peaked at $853K in Q4 2015.
539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2018.

Based on Lockheed Martin Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.